Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för peramivir hydrate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2015-03-06

Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.

Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Yoshinaga T, Naito A, Sato A.

Antiviral Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.antiviral.2015.02.012

Bibliografisk träff 2015-02-17

Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.04836-14

Bibliografisk träff 2015-01-01

A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK.

Wang ZZ, Zhang M, Shang DW, Ni XJ, Hu JQ, Qiu C, Wen YG.

Bioanalysis · research support, non-u.s. gov't; journal article · DOI 10.4155/bio.14.248

Bibliografisk träff 2014-12-29

Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.

Sato M, Ito M, Suzuki S, Sakuma H, Takeyama A, Oda S, Watanabe M, Hashimoto K, Miyazaki K, Kawasaki Y, Hosoya M.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.04263-14

Bibliografisk träff 2014-11-26

Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.

Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J.

J Infect Chemother · research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.jiac.2014.11.009

Bibliografisk träff 2014-09-30

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jiac.2014.08.030

Bibliografisk träff 2014-09-18

Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects.

Zhang D, Du A, Zhang L, Ma J, Meng L, Deng M, Xu J, Liu H.

Xenobiotica · randomized controlled trial; journal article · DOI 10.3109/00498254.2014.960907

Bibliografisk träff 2014-02-12

The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.

Tanaka A, Nakamura S, Seki M, Iwanaga N, Kajihara T, Kitano M, Homma T, Kurihara S, Imamura Y, Miyazaki T, Izumikawa K, Kakeya H, Yanagihara K, Kohno S.

Antivir Ther · research support, non-u.s. gov't; journal article · DOI 10.3851/imp2744